What is Predictive Biology?
Predictive Biology operates at the intersection of advanced genetics and stem cell biology, providing a sophisticated platform for the discovery of complex trait etiologies. Through the integration of organoid technology and single-cell analysis, the firm enables pharmaceutical and biotechnology partners to elucidate molecular mechanisms with unprecedented precision. Their proprietary panel of mouse ES cell lines serves as a cornerstone for phenotypic screening, allowing for the robust validation of novel drug targets. By bridging the gap between academic research and industrial application, Predictive Biology has established itself as a critical infrastructure provider for neuroscience, environmental toxicology, and therapeutic development.
How much funding has Predictive Biology raised?
Predictive Biology has raised a total of $58K across 1 funding round:
Debt
$58K
Debt (2021): $58K with participation from PPP
Key Investors in Predictive Biology
PPP
Public-Private Partnership
What's next for Predictive Biology?
With the recent infusion of capital, Predictive Biology is poised to scale its operational capacity and deepen its strategic partnerships across the global life sciences ecosystem. The company is expected to prioritize the expansion of its analytical technologies, further refining its in vitro genetics platform to meet the increasing demand for high-fidelity preclinical data. As the firm transitions through this growth phase, the focus will likely shift toward enhancing its throughput capabilities and broadening its therapeutic target pipeline. This strategic trajectory suggests a long-term commitment to setting new benchmarks in drug discovery efficiency and molecular mechanism validation, ultimately driving value for both its commercial partners and the broader scientific community.
See full Predictive Biology company page
